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Abstract
Heparanase is a heparan sulfate (HS) degrading endoglycosidase participating in extracellular matrix degradation and
remodeling. Apart of its well characterized enzymatic activity, heparanase was noted to exert also enzymatic-independent
functions. Non-enzymatic activities of heparanase include enhanced adhesion of tumor-derived cells and primary T-cells.
Attempting to identify functional domains of heparanase that would serve as targets for drug development, we have
identified heparin binding domains of heparanase. A corresponding peptide (residues Lys
158-Asp
171, termed KKDC) was
demonstrated to physically associate with heparin and HS, and to inhibit heparanase enzymatic activity. We hypothesized
that the pro-adhesive properties of heparanase are mediated by its interaction with cell surface HS proteoglycans, and
utilized the KKDC peptide to examine this possibility. We provide evidence that the KKDC peptide interacts with cell
membrane HS, resulting in clustering of syndecan-1 and syndecan-4. We applied classical analysis of cell morphology,
fluorescent and time-lapse microscopy and demonstrated that the KKDC peptide efficiently stimulates the adhesion and
spreading of various cell types, mediated by PKC, Src, and the small GTPase Rac1. These results support, and further
substantiate the notion that heparanase function is not limited to its enzymatic activity.
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Introduction
Proteoglycans are proteins that bear long, un-branched sugar
polymers, glycosaminoglycans, which are attached to specific
serine residues of the protein core [1]. Glycosaminoglycans are
polymers of disaccharide units. In the case of heparan sulfate,
uronic acid (either glucuronic acid or iduronic acid) and N-acetyl
glucosamine repeats compose the basic structure of the proteo-
glycan. Despite the seemingly simple, single repeating structural
motif, these sugar polymers show a great deal of structural
diversity generated by complex pattern of deacetylation, sulfation,
and epimerization [1]. Thus, a single heparan sulfate proteoglycan
(HSPG) side chain contains distinct structural domains, composed
of regions of highly sulfated, negatively-charged residues alongside
of regions with modest levels of sugar modifications. Proteoglycans
are abundant components of the basement membrane and
extracellular matrix (ECM) of epithelium, endothelium, and
connective tissues including cartilage, tendons, and bones [2,3].
In addition, proteoglycans are also abundantly present on the cell
surface, providing an important constituent of the cell’s sugar coat
involved in various aspects of cellular and molecular activities at
the cell-ECM interface [4]. By interacting with other macromol-
ecules such as laminin, fibronectin, and collagens I and IV,
HSPGs contribute to the structural integrity, self-assembly and
insolubility of the ECM and basement membrane, thus intimately
modulating cell-ECM interactions [5–7]. ECM constituents are,
however, only one class of HS-binding molecules. In fact,
numerous enzymes, growth factors, cytokines and chemokines
are sequestered by HSPGs on the cell surface and ECM [1,4,8,9].
In general, HSPGs facilitate the biological activity of bound
ligands by actively participating in receptor-ligand complex
formation [10]. In other cases, HSPGs mediate cellular uptake
and catabolism of selected ligands [10], or sequester polypeptides
to the ECM and cell surface as an inactive reservoir [11–15].
Cleavage of HSPGs would ultimately release these proteins and
convert them into bioactive mediators, ensuring rapid tissue
response to local or systemic cues. The protein core of HSPGs is
susceptible to cleavage by several classes of proteases [16,17]. An
additional mode of HSPGs cleavage is offered by the enzyme
heparanase.
Heparanase is an endo-b-glucuronidase that cleaves HS side
chains presumably at sites of low sulfation [18], releasing
saccharide products with appreciable size (5–7 kDa) that can still
associate with protein ligands and modulate their biological
potency. Heparanase activity has been traditionally correlated
with cell invasion associated with cancer metastasis, a consequence
of structural modification that loosens the ECM barrier [19–21].
More recently, heparanase up-regulation was documented in an
increasing number of human carcinomas and hematological
malignancies [18,22–25]. In many cases, heparanase induction
correlated with increased tumor metastasis, vascular density, and
shorter post operative survival rate, thus providing a strong clinical
support for the pro-metastatic and pro-angiogenic function of the
enzyme [22,25]. In addition to the well studied catalytic feature of
the enzyme, heparanase was noted to exert biological functions
apparently independent of its enzymatic activity. Non enzymatic
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[26], lymphoma [27] and T cells [28], mediated by b1-integrin
and correlated with Akt, Pyk2 and ERK activation [26,28].
Attempting to identify functional domains that would serve as a
target for drug development, we have recently identified heparin
binding domains of heparanase [29]. A corresponding peptide
(residues Lys
158-Asp
171, termed KKDC) was demonstrated to
physically associate with heparin and HS, and to inhibit
heparanase enzymatic activity [29]. We hypothesized that the
pro-adhesive properties of heparanase are mediated by its
interaction with cell surface HSPGs and utilized the unique
feature of the KKDC peptide to examine this possibility.
Syndecans are a family of four transmembrane proteins capable
of carrying chondroitin sulfate (CS) and HS chains. Syndecans are
expressed on virtually all cell types throughout development and
adulthood, and their expression can be altered under certain
pathophysiological conditions, including tumor onset, progression,
and metastasis [30,31]. The presence of HS chains allows
interactions with a large number of proteins, including heparin-
binding growth factors, plasma proteins such as antithrombin, and
extracellular matrix proteins including fibronectin. In addition,
syndecans are thought to function as co-receptors, facilitating
growth factors, morphogens, and integrins activity [30–32].
Furthermore, syndecans can associate with a large number of
adaptor and signaling molecules through their cytolplasmic tail,
despite being relatively small. These include ezrin, tubulin,
cortactin, PDZ domain-containing proteins (i.e., syntenin), Src
and PKCa [33,34]. Syndecans emerge as central players in the
interactions between the ECM and the cell surface that ultimately
regulate cell spreading, adhesion, and migration. This function
was largely attributed to a direct interaction of syndecans with
matrix proteins such as fibronectin. In addition, clustering of
syndecan-4 has been shown to initiate signaling cascades that
results in PKCa and Rac1 activation that appears instrumental for
cell adhesion and directional migration [33–37].
Here, we provide evidence that the KKDC peptide interacts
with plasma membrane HS, and facilitates clustering of syndecan-
1 and syndecan-4. Interestingly, while the heparanase-syndecan
complex is subjected to rapid internalization and appears in
endocytic vesicles short after the addition of heparanase, the
KKDC peptide elicits syndecan clusters that remain on the cell
surface for a relatively long period of time and fail to get
internalized. We demonstrate that the KKDC peptide efficiently
stimulates the adhesion and spreading of multiple cell types by
activating the PKC pathway and the small GTPase Rac1. These
results support and further expand the notion that heparanase
function is not limited to its enzymatic activity, and highlight
heparin binding domains as targets for the development of anti-
cancer inhibitors.
Materials and Methods
Antibodies and reagents
Anti syndecan-1 monoclonal antibody (B-B4) was purchased
from Serotec (Oxford, UK). Antibodies to syndecan-4 and paxillin
were purchased from Santa Cruz Biotechnology (Sanata Cruz,
CA). Anti-Rac 1 monoclonal antibody was purchased from Becton
Dickinson Biosciences (San Diego, CA), and PAK PBD-agarose
beads were from Cell Biolabs Inc (San Diego, CA). Anti-vinculin
monoclonal antibody, phalloidin-TRITC, heparin, fibronectin,
and the 110 kDa fibronectin-like genetically engineered protein,
were purchased from Sigma (St. Louis, MO). Avidin-FITC was
purchased from Vector (Burlingame, CA). The selective p38 (SB-
203580), Src (PP2), Erk (PD-98059), PKC [Bisindolylmaleimide I
(Bis)], Rock (Y27632) and Rac (NSC 23766) inhibitors were
purchased from Calbiochem (San Diego, CA) and were dissolved
in DMSO as stock solutions. DMSO was added to the cell culture
as a control. The KKDC and its control, scrambled peptide were
synthesized as described previously [29]. The introduced C-
terminal cysteine residue mediates spontaneous peptide dimeriza-
tion that can be further facilitated by enhanced oxygenation
generated by stirring. For biotin labeling, an extra lysine residue
was introduced at position 12 to create the sequence
KKFKNSTYSRSK
biotinSVDC. This approach was undertaken
in order to preserve the N-terminal lysine residues critical for the
peptide interaction with HS [29]. A peptide from the COOH-
terminal heparin-binding domain of fibronectin (Hep II peptide,
WQPPRARI) [38] was purchased from Sigma (St. Louis, MI).
Cells and cell culture
U87 MG human glioma and Colo 320 colon carcinoma cells
were purchased from the American Type Culture Collection
(ATCC). Rat C6 glioma cells were kindly provided by Dr. Eli
Keshet (The Hebrew University Hadassah Medical School,
Jerusalem) [39], and human skin fibroblasts were kindly provided
by Dr. H. Mendel (Rambam Health Care Campus, Haifa). ARH-
77 leukemia-derived F cells were kindly provided by Dr. Ben-Zion
Katz (Soraski Medical Center, Tel-Aviv, Israel). F cells are a sub-
population of the ARH-77 cell line which poorly adhere and
mainly floats (F) once plated on fibronectin-coated dishes [40].
Cells were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with glutamine, pyruvate, antibiotics
and 10% fetal calf serum in a humidified atmosphere containing
5% CO2 at 37uC. Wild type Chinese hamster ovary (CHO) K1
and mutant cells (pgs A-745) deficient in xylosyltransferase and
unable to initiate glycosaminoglycan synthesis, were kindly
provided by Dr. Jeffery Esko (University of California, San Diego),
and grown in RPMI 1640 medium supplemented with 10% FCS
and antibiotics [39]. Recombinant wild type and enzymatically-
inactive heparanase mutated at glutamic acid residues 225 and
343 [double mutant (DM)] critical for enzymatic catalysis [41]
were purified from the conditioned medium of HEK 293
transfected cells, essentially as described [42].
Cell morphology and immunocytochemistry
Cells were plated on glass cover slips uncoated or coated with
fibronectin or the 110 kDa fibronectin-like protein for the time
indicated in the absence (Con) or presence of the indicated
peptides [scrambled (Scr), or KKDC; (50 mg/ml)], proteins [latent
65 kDa or mutated, enzymatically inactive heparanase (1 mg/ml)],
or inhibitors. Cells were then fixed with 4% paraformaldehyde in
PBS for 15 minutes, and visualized. For immunofluorescent
staining, cells were fixed with cold methanol for 10 minutes,
washed with PBS and subsequently incubated in PBS containing
10% normal goat serum for 1 hour at room temperature, followed
by 2 hours incubation with the indicated primary antibody. Cells
were then extensively washed with PBS and incubated with the
relevant Cy2/Cy3-conjugated secondary antibody (Jackson Im-
munoResearch, West Grove, PA) for 1 hour, washed and mounted
(Vectashield, Vector, Burlingame, CA). Staining was observed
under a fluorescent confocal microscope. For actin staining, cells
were fixed with 4% paraformaldehyde, permeabilized with 0.5%
triton X-100 for 2 minutes, washed and incubated with TRITC-
phalloidin (Sigma) for 30 minutes and visualized by confocal
microscopy, as described [43,44].
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Cell cultures were incubated for 24 hours under serum-free
conditions, pretreated with 1 mM orthovanadate for 10 minutes
at 37uC, washed twice with ice cold PBS containing 1 mM
orthovanadate and scraped into lysis buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% Triton-X100, 1 mM orththovana-
date, 1 mM PMSF) containing a cocktail of protease inhibitors
(Roche, Mannheim, Germany). Total cellular protein concentra-
tion was determined by the BCA assay, according to the
manufacturer’s (Pierce, Rockford, IL) instructions. Thirty micro-
grams of cellular protein were subjected to SDS polyacrylamid gel
(SDS-PAGE) and immunoblotting, as described [29,45]. For
estimation of Rac1 activation, lysis buffer included 50 mM Tris-
HCl, pH 7.4, 300 mM NaCl, 10 mM MgCl, 4% glycerol, and 1%
Triton X-100. The amount of GTP-bound Rac1 was analyzed by
incubating total cell lysates (200 mg) with 20 mg of the p21-binding
domain (PBD) of PAK-agarose beads. Following 30 minutes
incubation, the beads were washed and, after electrophoresis
and blotting, membranes were probed with anti-Rac1 antibodies
[26].
Time Lapse microscopy
Cells were grown on Corning/Nunc 6 wells dishes in DMEM
medium and viewed with inverted motorized microscope
(DMIRE2 Leica, Germany). Images were captured using cooled
B/W CCD camera (Retiga EXI, Qimaging, USA). Time-lapse
acquisition was made with custom written software (Provided by
Uri Alon, Weizmann Institute, Rehovot, Israel), inserted into
Image-Pro software (MediaCybernetics, USA). The system is
equipped with an on stage incubator (Cube & Box, LIS,
Switzerland).
Results
The KKDC peptide interacts with the plasma membrane
We have identified heparin binding domains that mediate the
interaction of heparanase with its HS substrate and demonstrated
that a peptide corresponding to Lys
158-Asn
171 (KKDC), inhibits
heparanase enzymatic activity [29]. Although the KKDC peptide
has been shown to physically interact with heparin and HS [29],
binding and localization at the cellular level have not been so far
demonstrated. For this purpose, the KKDC and control,
scrambled peptides were labeled with biotin on an extra lysine
residue introduced in order to maintain the N-terminal lysine
residues critical for HS binding [29] intact, and peptide binding
was detected by Avidin-FITC. No detectable binding of the
control, scrambled peptide to CHO K1 cells was observed (Fig. 1A,
Scr). In contrast, the KKDC peptide gave rise to a punctuated,
readily detected staining (Fig. 1A, KKDC) that was significantly
reduced by the addition of heparin (Fig. 1A, KKDC+heparin).
Furthermore, no staining was detected upon addition of the
biotinylated KKDC peptide to CHO-745 cells deficient of HSPGs
(Fig. 1A, KKDC/745), suggesting that the KKDC peptide
interacts with cell surface HSPGs. Interaction of the KKDC
peptide with cell membrane molecules, lack of interaction with
CHO-745 cells, and heparin competition were further demon-
strated by FACS analysis (Fig. 1B). Thus, the KKDC peptide
enables to elucidate the effect of heparanase-HS interaction on cell
Figure 1. The KKDC peptide interacts with plasma membrane heparan sulfate. A,B: peptide binding. Wild type (CHO K1; a–c) and heparan
sulfate-deficient (CHO-745; d) cells were incubated (2 hours) with biotinylated KKDC (b–d) or control peptide (Scr; a) in the absence (a, b, d) or
presence (c) of 10 mg/ml heparin. Cells were then washed, fixated with 4 % paraformaldehyde and bound peptide was visualized with avidin-FITC and
fluorescence microscopy (A) or analyzed by FACS Scan (B). C, D Heparanase and the KKDC peptide promotes cell adhesion. Leukemia-derived ARH-77
cells that were selected to grow in suspension (F cells), were plated on fibronectin coated plates for 30 minutes in the presence of heparanase (Hepa;
1 mg/ml), inactive heparanase (DM; 1 mg/ml), KKDC peptide (50 mM), or control peptide (Scr, 50 mM). Plates were gently washed and cell adhesion
was visualized by light microscopy (C). Adherent cells were counted and quantified (D).
doi:10.1371/journal.pone.0002319.g001
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such as low density lipoprotein receptor-related protein (LRP) and
the mannose 6-phosphate receptor (MPR) [46].
Inactive heparanase facilitates leukemia cell adhesion
We have previously noted that over expression of heparanase
enhances the adhesion of mouse Eb lymphoma cells to ECM and
endothelial cells. Augmented cell adhesion was maintained by cells
transfected with point mutated, inactive heparanase, or in the
presence of laminaran sulfate, an inhibitor of heparanase
enzymatic activity [27], arguing for enzymatic-independent
function. Similarly, exogenous addition of purified latent 65 kDa
heparanase to poorly adhesive human leukemia ARH-77 F cells,
selected to grow in suspension [40], significantly enhanced their
adhesion to fibronectin (Fig. 1C&D, Hepa). Moreover, addition of
recombinant, enzymatically inactive double mutated (DM)
heparanase facilitated F cells adhesion similar in magnitude to
the wild type protein (Fig. 1C&D, DM), further supporting the
notion that improved cellular adhesion upon heparanase over-
expression [27] or exogenous addition (Fig. 1) does not involve
enzymatic aspects.
The scope of heparanase function has recently been challenged
by evidence documenting its ability to activate signaling molecules
(i.e., Akt, p38, Src) in an enzymatic-independent manner, resulting
in enhanced gene transcription [42,47] and cell adhesion [26–28].
Enhanced cell adhesion by heparanase may be due to binding and
activation of plasma membrane proteins such as syndecans, a class
of trans-membrane HSPGs shown to modulate adhesion com-
plexes [30,31,34]. In order to examine this possibility, we took
advantage of the specific feature of the KKDC peptide and
exposed ARF-77 F cells to the KKDC peptide or its control,
scrambled counterpart. Indeed, the KKDC peptide elicited a
significant, two-fold increase in F cells adhesion (Fig. 1C&D,
KKDC), while the control, scrambled peptide had no such effect
(Fig. 1C, Scr). These results suggest that interaction between
heparanase and plasma membrane HSPGs is sufficient to enhance
cell adhesion.
The KKDC peptide induces syndecan clustering and
enhances cell spreading
Syndecan-4 appears regularly spread in the plasma membrane
of U87 glioma cells (Fig. 2, upper panels, Scr). In contrast,
syndecan-4 was mostly localized to perinuclear endocytic vesicles
following heparanase addition (Fig. 2, upper panels, Hepa), co-
localizing with heparanase [39]. Interestingly, however, syndecan-
4 was not internalized upon the addition of the KKDC peptide but
rather appeared clustered on the cell surface (Fig. 2, upper panels,
KKDC). A similar localization was noted for syndecan-1 (Fig. 2,
middle panel, KKDC). Next, we examined U87 cell spreading
upon stimulation with heparanase or the KKDC peptide by
staining the cells for paxillin, a well-characterized focal-adhesion
component. Cells treated with heparanase (1 mg/ml) appeared
better spread and focal adhesion complexes were nicely decorated
by paxillin (Fig. 2, lower panels, Hepa, arrows). Enhanced cell
spreading was even more pronounced in the presence of the
KKDC peptide (50 mM), where multiple focal contacts appeared
(Fig. 2, lower panels, KKDC), indicating that syndecans clustering
by the KKDC peptide facilitates cellular spreading. These
observations were further confirmed by employing several
additional cell adhesion systems.
Rat C6 glioma cells rapidly adhere and spread once plated on
tissue culture plastic dish. The cells, however, assume a round
morphology once cultured in serum-free medium, and remained
round following the addition of control peptide (Fig. 3A, Scr;
Movie S1). In striking contrast, cells appeared nicely spread
following the addition of heparanase (Fig. 3A, Hepa; Movie S2)
and even more so the KKDC peptide (Fig. 3A, KKDC; Movie
S3), an effect that was completely inhibited by heparin (Fig. 3A,
lower panels; Movie S4). Similarly, treatment of Colo 320 colon
carcinoma cells with the KKDC peptide enhanced cell spreading
(Fig. 3B, KKDC) and focal complexes formation evident by
paxillin staining (Fig. 3B, KKDC, inset).
Fibronectin is a multifunctional glycoprotein that mediates a
number of important biological functions including cell adhesion
and migration [48]. The diverse biological activities attributed to
fibronectin have been localized to specific molecular domains.
Thus, the main cell binding, RGD-rich domain is localized within
the 10
th type III module, while heparin binding is mediated by
modules 12–14 [49]. Fibronectin-like protein polymer has been
engineered to include 13 copies of the RGD-rich sequence,
resulting in a protein with a stable three-dimensional conformation
and molecular mass of 110 kDa. CHO K1 cells plated on dishes
coated with the 110 kDa fibronectin-like protein adhered, but
failed to spread and appeared round in morphology (Fig. 4, Scr,
upper panel), as expected [32]. In contrast, CHO K1 cells plated
on the fibronectin-like protein in the presence of heparanase
(Fig. 4, Hepa) or the KKDC peptide appeared elongated and
more spread (Fig. 4, upper panels). In addition, cells treated with
heparanase exhibited typical membrane protrusions (Fig. 4, inset),
and actin stress fibers were evident in cells treated with the KKDC
peptide (Fig. 4, inset). Similarly, enhanced stress fiber and focal
complexes formation, evident by phalloidin and vinculin staining,
respectively, were noted in human fibroblasts plated on the
110 kDa fibronectin-like polymer substrate and treated with
heparanase or the KKDC peptide (Fig. 4, lower panels).
Collectively, these results suggest that syndecan clustering by
heparanase or the KKDC peptide facilitates cell adhesion and
spreading and can substitute, to some extent, the heparin binding
domains of fibronectin.
Enhanced cell spreading by heparanase/KKDC is
mediated by PKC, Src, and Rac1
As shown above, CHO K1 cells depend on heparanase or the
KKDC peptide for spreading on the 110 kDa fibronectin-like
substrate (Fig. 4). We, next, utilized this cell system to examine
signaling pathways that mediate the effect of heparanase. To this
end, cells were plated on the 110 kDa fibronectin-like substrate
without (Con, Fig. 5) or with heparanase (Fig. 5, Hepa), or
pretreated with the indicated inhibitor prior to heparanase
addition, and cell spreading was then examined. As previously
noted, CHO K1 cells spreading was markedly enhanced in the
presence of heparanase (Fig. 5, Hepa). Cell spreading stimulated
by heparanase was not significantly altered by inhibitors of MAPK
(Fig. 5, Hepa+PD), PKA (Fig. 5, Hepa+H89), or ROCK, a down
stream effector of RhoA (Fig. 5, Hepa+Y27632). In contrast, cell
spreading stimulated by heparanase was significantly attenuated
by Src (Fig. 5, Hepa+PP2), PKC (Fig 5, Hepa+Bis), and Rac1
(Fig. 5, Hepa+NSC 23766) inhibitors. The small GTPase Rac1 is
thought to play instrumental roles in the early phases of cell
adhesion and spreading [50]. Thus, initial membrane protrusion is
governed by Cdc42 and Rac1 activation, resulting in filopodia/
lamellipodia extensions and focal complexes formation. Subse-
quent activation of RhoA induces the maturation of focal
complexes to focal adhesions, assembly of stress fibers, and cell
locomotion [50]. Given the observed enhancement of cell
adhesion and spreading upon heparanase/KKDC treatment, we
examined RhoA and Rac1 activation by employing agarose beads
coupled to RhoA-binding domain of Rhotekin, and the p-21
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specifically binds the active, GTP-bound form of RhoA and Rac1,
respectively. Rac1 activation was markedly induced following
heparanase addition to ARF-77 leukemia F cells (Fig. 6A, Hepa,
upper panel). Double-mutated, inactive heparanase (DM) and the
KKDC peptide stimulated Rac1 activation to the same extent
(Fig. 6A, DM, upper panel) or even higher (KKDC) than wild type
heparanase (Fig. 6A, upper panel). Similarly, a significant
activation of Rac1 was noted in U87 glioma cells stimulated with
heparanase or the KKDC peptide (Fig. 6B, upper panel),
activation that was abolished by the addition of heparin
(Fig. 6B+heparin), while RhoA activation was not evident (not
Figure 2. The KKDC peptide induces syndecan clustering and enhances cell spreading. U87 cells were serum starved for 24 hours and
were then incubated with the KKDC/Scr peptides (50 mM) or heparanase (1 mg/ml) for 1 hour. Cells were then gently washed, fixed with cold
methanol and subjected to fluorescent staining with anti-syndecan-4 (upper panels) or anti-syndecan-1 (middle panels) antibodies. U87 cells were
also plated on the 110 kDa fibronectin-like protein and incubated for 4 hours in the presence of KKDC/Scr peptides (50 mM) or heparanase (1 mg/ml).
Cells were then washed, fixed with 4% paraformaldehyde and stained with anti-paxillin antibodies (lower panels).
doi:10.1371/journal.pone.0002319.g002
Figure 3. The KKDC peptide induces cell spreading. A. C6 glioma cells were serum-starved for 24 hours, and were then incubated with
heparanase (1 mg/ml), KKDC or control (Scr) peptides (50 mM) for 18 hours in the absence (upper panels) or presence of heparin (50 mg/ml; lower
panels). Cell spreading was evaluated by light microscopy. B. Colo320 colon carcinoma cells were plated on fibronectin for 1 hour followed by
incubation with the KKDC (lower panel) or the control (Scr; upper panel) peptides (50 mM) for additional 18 hours. Cell spreading was evaluated by
light microscopy and by staining for paxillin (insets).
doi:10.1371/journal.pone.0002319.g003
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localization following heparanase or KKDC stimulation
(Fig. 6C), a cellular translocation that is considered essential for
the activation of down stream effectors, and cell migration [51].
Altogether, the results indicate that syndecan activation by
soluble heparanase is sufficient to stimulate cell adhesion, function
that clearly does not require heparanase enzymatic activity and is
efficiently mimicked by the KKDC peptide.
Discussion
We have previously noted that heparanase facilitates the
adhesion, spreading, and migration of several cell types in a
manner that appeared independent of its enzymatic activity [26–
28,52]. We have also noted that heparanase is internalized as a
complex with syndecan family members [39], and induces Rac1
activation [26], yet the causal link between these observations was
unclear. The results presented in this study merge these findings in
a linear mode in which syndecan clustering by heparin binding
domains of heparanase initiates signaling cascades that involve
Rac1, Src, and the PKC pathways, resulting in enhanced cell
adhesion and spreading (Fig. 7). Syndecan clustering and
activation are likely mediated by the two functional heparin
binding domains of heparanase (Lys
158-Asp
171 and Gln
270-Lys
280)
[29], which are mimicked by the KKDC peptide dimer. These
results not only provide a molecular basis for non-enzymatic
function of heparanase, but also suggest a novel mechanism by
which syndecan molecules are activated. Thus, while syndecan
clustering is thought to be mediated physiologically by ECM
resident fibril fibronectin, or artificially engaged by antibodies
[37], our results suggest that syndecans can also be activated by
soluble ligands such as heparanase.
A key tool for deciphering this mode of heparanase function is
provided by the KKDC peptide. A cysteine residue introduced at
the peptide C-terminus mediates spontaneous peptide dimeriza-
tion that can be further facilitated by enhanced oxygenation, a
Figure 4. Heparanase and the KKDC peptide enhance cell spreading and formation of actin stress fibers. CHO cells (a–c) and human
fibroblasts (d–f) were plated on the 110 kDa fibronectin-like protein and incubated with heparanase (Hepa; 1 mg/ml) or the KKDC/Scr peptides
(50 mM) for 18 hours (a–c) or 1 hour (d–f). Cells were then visualized by light microscopy (a–c) or fixed with 4% paraformaldehyde and stained with
phalloidin-TRITC (a–c, insets) or double stained with phalloidin-TRITC (red) and anti-vinculin (green) antibody (d–e). Cells treated with heparanase
(b,e) or with the KKDC peptide (c,f) appeared spread and formed more focal adhesions (e,f).
doi:10.1371/journal.pone.0002319.g004
Figure 5. Cell spreading induced by heparanase is mediated by PKC, Rac, and Src. CHO cells were plated on the 110 kDa fibronectin-like
protein, without (Con) or with heparanase, in the absence (Hepa) or presence of selective PKC (Bis), Src (PP2), ROCK (Y27632), MAPK (PD), PKA (H89),
and Rac (NSC 23766) inhibitors for 6 hours. Cells were then fixed with 4% paraformaldehyde and stained with phalloidin-TRITC.
doi:10.1371/journal.pone.0002319.g005
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heparin [53], yielding a two-headed molecule with intact heparin
binding domains at both ends (Fig. 7). Indeed, the addition of
ethandithiol (EDT) which binds covalently to the sulfate group of
cysteine and prevents di-sulfide bridge formation between cysteine
residues, markedly inhibited the interaction of the KKDC peptide
with heparin (Fig. S1A) and its anti-heparanase activity (not
shown). Thus, the peptide dimer and its two-headed heparin
binding domains mimic the two functional heparin binding
domains of heparanase [29], and enables syndecan clustering
(Fig. 7). In fact, syndecan clusters elicited by the KKDC peptide
appeared exceptionally large and failed to get internalized at the
time points examined, while the heparanase-syndecan complex is
rapidly and efficiently internalized (Fig. 2) [39]. The ability of the
KKDC peptide to interact with heparin [29] and to cluster
syndecans (Fig. 2) appears unique, since peptides derived from two
additional domains in heparanase containing a Cardin-Weintraub
consensus sequences and suspected to mediate its interaction with
heparan sulfate (Gln
270-Lys
280 and Lys
411-Arg
432) exhibited only a
very weak interaction with heparin and failed to inhibit
heparanase enzymatic activity [29]. Thus, the mere presence of
Cardin-Weintraub consensus sequences [9] appears not sufficient
to ensure bioactive peptide, further highlighting the unique feature
of the KKDC peptide. Moreover, a peptide derived from the C-
terminal heparin-binding domain of fibronectin failed to facilitate
the adhesion of ARH-77 leukemia-derived F cells, compared with
a significant pro-adhesive effect exerted by the KKDC peptide
(Fig. S2 and data not shown). Notably, cells treated with the
KKDC peptide appeared better spread and formed more focal
contacts compared with cells treated with heparanase. This was
evident by the morphology of C6 and Colo 320 cells (Fig. 3),
paxillin staining of U87 glioma (Fig. 2) and Colo 320 cells (Fig. 3B),
and phalloidin and vinculin staining of CHO and human skin
fibroblasts plated on the 110 kDa fibronectin-like substrate (Fig. 4),
indicating that syndecan clustering by the KKDC peptide is
translated biochemically to cellular response. In contrast, hepar-
anase appeared more efficient in stimulating the adhesion of
floating ARH-77 leukemia cells compared with the KKDC
peptide (Fig. 1). This result indicates that syndecan activation
alone by the KKDC peptide may not be sufficient for efficient cell
adhesion, and that cooperation with additional adhesion molecules
such as integrins is required [32]. Integrin activation was noted
upon heparanase over expression or exogenous addition [26,28].
Figure 6. Heparanase and the KKDC peptide induce Rac1
activation. A. F cells were washed with serum free medium and were
then treated for 30 minutes with the KKDC/Scr peptides (50 mM), wild
type heparanase (Hepa) or inactive double mutant heparanase (DM) in
serum free medium. Cell lysates (100 mg) were then subjected to pull-
down with GST-PAK-agarose beads for detection of active Rac1 (upper
panels), as described in ‘‘Materials and Methods’’. Cell lysates (30 mg)
were subjected to immunoblotting with anti-Rac1 antibody (lower
panels). B. U87 cells were kept in serum-free medium for 24 hours and
were then stimulated with the KKDC/Scr peptides (50 mM) or
heparanase (Hepa; 1 mg/ml) for 30 min without or with heparin
(50 mg/ml; +heparin). Rac activation was then evaluated as above. C.
Human umbilical vein endothelial cells (HUVEC) were plated on the
110 kDa fibronectin-like protein and were incubated with the KKDC/Scr
peptides (50 mM) or heparanase (Hepa; 1 mg/ml) for 3 hours. Cells were
then fixed and stained with anti-Rac1 antibody. Note Rac1 localization
to the plasma membrane (arrows) following treatment with heparanase
or the KKDC peptide.
doi:10.1371/journal.pone.0002319.g006
Figure 7. A schematic diagram of HSPG activation by heparanase/KKDC. Clustering of syndecan family members, and possibly glypicans, by
the KKDC dimer or the two heparin binding domains of heparanase facilitates cell-adhesion and cell-spreading (left). Enhanced cell adhesion and
spreading is mediated by the recruitment and activation of PKCa, Rac1, and Src. In addition, heparanase is thought to interact with heparanase-
binding cell surface protein/receptor, leading to HS-independent Akt activation. Similarly, p38 and Src activation by heparanase may also be
mediated by this receptor, resulting in enhanced transcription of genes such as vascular endothelial growth factor (VEGF) [42], tissue factor (TF) [47],
or Cox2 [60], and further contribute to cell adhesion, spreading and motility (right).
doi:10.1371/journal.pone.0002319.g007
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mutated, inactive heparanase (DM) was as potent as wild type
heparanase in facilitating ARH-77 F cell adhesion (Fig. 1). The
molecular mechanism underlying integrin activation by hepar-
anase awaits detailed characterization.
The prime syndecan candidate for mediating the effect of
heparanase/KKDC on cell adhesion is syndecan-4 since this
molecule is ubiquitously expressed and is the only syndecan that
appears to reside at, and exhibit a functional role in the assembly
of focal adhesions [31,34,54]. The KKDC peptide, however,
clustered efficiently both syndecan-1 and syndecan-4 (Fig. 2) and
possibly additional syndecan family members, raising the possibil-
ity that enhanced cell adhesion and spreading is not solely
mediated by syndecan-4. Indeed, essentially all syndecan family
members are implicated in cell adhesion. For example, over
expression of syndecan-1 in syndecan deficient Raji lymphoblas-
toid or COS-7 cells stimulated cell spreading [30]. Similarly,
syndecan-2 was noted to promote focal adhesion formation in
Lewis-lung carcinoma cells [31], and syndecan-2 and syndecan-3
induce filopodia formation in COS-1, CHO-K1, Swiss 3T3, and
dendritic cells [30,33,55]. It is therefore likely that heparanase/
KKDC induce the clustering of more than one syndecan family
member and, possibly, also of glypicans, leading to enhanced cell
adhesion and spreading. This possibility is further supported by
the localization of syndecans following the addition of heparanase
or the KKDC peptide. Clusters of syndecan-1 and syndecan-4
were similarly distributed on the cell surface following addition of
the KKDC peptide (Fig. 2) in a pattern that does not coincide with
focal complexes. Rapid internalization of heparanase-syndecan
complexes following heparanase addition clearly implies that
enhanced cell adhesion does not require localization of syndecans
at focal adhesions, but rather involves syndecan activation.
Syndecan activation by soluble ligands such as heparanase may
also have important clinical implications. Over expression of
syndecan-1 has been observed in pancreatic, gastric and breast
carcinomas, correlating with increased tumor aggressiveness and
poor clinical prognosis, while syndecan-2 is often over expressed in
colon carcinoma, and syndecan-4 is up-regulated in hepatocellular
carcinoma [30], coinciding with heparanase up-regulation in these
carcinomas [22,25]. Syndecan-1 is particularly abundant in
multiple myeloma [56], where an emerging role for heparanase
has recently been shown [57–59]. Thus, elevated levels of
heparanase may activate syndecan family members and promote
tumor metastasis and angiogenesis, resulting in poor prognosis
often associated with patients exhibiting high levels of heparanase
[22,25].
Taken together, the results clearly highlight heparanase as a
multi functional protein, exhibiting enzymatic activity-dependent
and -independent functions. Better understanding of the basic
biology of this protein will contribute to the development of
efficient heparanase inhibitors directed, for example, against the
heparin binding domains of heparanase [29,44]. Monoclonal
antibodies or small molecules directed against this domain will not
only inhibit heparanase enzymatic activity [44], but will also
suppress syndecans activation, resulting in a more efficient
neutralization of heparanase functions. On the other hand, the
anti-cancer efficacy of the KKDC peptide which inhibits
heparanase enzymatic activity [44] (Fig. S1B) is questionable
taking into account its pro-adhesive properties.
Supporting Information
Movie S1 Time lapse microscopy. Rat C6 glioma cells (26104)
were plated in a 6-well plate in complete growth medium, followed
by 20 hours incubation in serum-free medium. Cells were then
incubated with control scrambled peptide. Six fields in each well
were randomly selected, and were examined every 10 min for
10 hours by the time lapse system. Representative time lapse
movie is shown.
Found at: doi:10.1371/journal.pone.0002319.s001 (6.15 MB AVI)
Movie S2 Time lapse microscopy. Rat C6 glioma cells (26104)
were plated in a 6-well plate in complete growth medium, followed
by 20 hours incubation in serum-free medium. Cells were then
incubated with heparanase (1 mg/ml); Six fields in each well were
randomly selected, and were examined every 10 min for 10 hours
by the time lapse system. Representative time lapse movie is
shown.
Found at: doi:10.1371/journal.pone.0002319.s002 (7.14 MB AVI)
Movie S3 Time lapse microscopy. Rat C6 glioma cells (26104)
were plated in a 6-well plate in complete growth medium, followed
by 20 hours incubation in serum-free medium. Cells were then
incubated with the KKDC peptide; Six fields in each well were
randomly selected, and were examined every 10 min for 10 hours
by the time lapse system. Representative time lapse movie is
shown.
Found at: doi:10.1371/journal.pone.0002319.s003 (6.99 MB AVI)
Movie S4 Time lapse microscopy. Rat C6 glioma cells (26104)
were plated in a 6-well plate in complete growth medium, followed
by 20 hours incubation in serum-free medium. Cells were then
incubated with the KKDC peptide with heparin (10\mg/ml); Six
fields in each well were randomly selected, and were examined
every 10 min for 10 hours by the time lapse system. Represen-
tative time lapse movie is shown.
Found at: doi:10.1371/journal.pone.0002319.s004 (6.15 MB AVI)
Figure S1 KKDC peptide dimerization significantly improves
heparin binding and anti-heparanase properties. A. Heparin
binding. KKDC peptide was synthesized in the absence (KKDC)
or presence of ethandithiol (EDT), which binds covalently to the
sulfate group of cysteine and prevents di-sulfide bridge formation
between cysteine residues. Peptides (50 mM) were incubated
(2 hours, 4uC) with heparin-Sepharose beads in PBS, washed
with PBS supplemented with NaCl to a final concentration of
0.35 M, followed by one wash with PBS. Dye-free sample buffer
was added and the beads were boiled for 5 minuntes, centrifuged
and the supernatants were loaded on Tris-Tricine gel. Subse-
quently, gels were stained with Coomassie blue to visualize bound
peptides (arrow). B. Heparanase enzymatic activity. B16 melano-
ma cells (26106) were resuspended in RPMI medium and
incubated (18 hours, 37uC) with 35S-labeled ECM in the absence
(filled rectangle) or presence of control scrambled peptide dimer
(green rectangle; 50 mM), KKDC peptide undergoing spontane-
ous dimerization (filled triangle; 50 mM), KKDC peptide following
enhanced dimerization (blue rectangle; 50 mM), or heparin (filled
circle; 15 mg/ml). The incubation medium (1 ml) containing
sulfate labeled degradation fragments was subjected to gel
filtration on a Sepharose CL-6B column. Fractions (0.2 ml) were
eluted with PBS and their radioactivity counted in a beta-
scintillation counter. Degradation fragments of HS side chains are
eluted at 0.5,Kav,0.8 (peak II, fractions 15–40) and represent
heparanase degradation products.
Found at: doi:10.1371/journal.pone.0002319.s005 (0.61 MB TIF)
Figure S2 Leukemia-derived ARH-77 cells that were selected to
grow in suspension (F cells), were plated on gelatin coated plates
for 30 minutes in the presence of the KKDC (50 mM), Hep II
(100 mM), or control (Scr) peptide (50 mM). Plates were then
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PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2319gently washed and cell adhesion was visualized by light
microscopy.
Found at: doi:10.1371/journal.pone.0002319.s006 (0.31 MB TIF)
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